Investigation of immunological approaches to enhance engraftment in a 1 Gy TBI canine hematopoietic stem cell transplantation model

Experimental Hematology

Volumn 37, Issue 1, 2009, Pages 143-150

  Lange, Sandra ^a   Altmann, Simone ^a   Brandt, Bettina ^a   Adam, Carsten ^a   Riebau, Franziska ^a   Vogel, Heike ^a   Weirich, Volker ^a   Hilgendorf, Inken ^a   Storb, Rainer ^b   Freund, Mathias ^a   Junghanss, Christian ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; LEUKOCYTE ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD TOXICITY; CELL LYSATE; CELL PROLIFERATION; CHIMERA; CONDITIONING; CONTROLLED STUDY; DENDRITIC CELL; DOG; ENGRAFTMENT; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGICAL TECHNIQUE; IMMUNOSUPPRESSIVE TREATMENT; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; T LYMPHOCYTE; VACCINATION; WHOLE BODY RADIATION;

ANIMALS; DOGS; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

ANIMALIA; CANIS FAMILIARIS;

EID: 57549112216     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2008.09.011     Document Type: Article

References (32)

1. Storb R., Yu C., Wagner J.L., et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89 (1997) 3048-3054
2. Prigozhina T.B., Gurevitch O., Zhu J., and Slavin S. Permanent and specific transplantation tolerance induced by a nonmyeloablative treatment to a wide variety of allogeneic tissues: I. Induction of tolerance by a short course of total lymphoid irradiation and selective elimination of the donor-specific host lymphocytes. Transplantation 63 (1997) 1394-1399
3. Pelot M.R., Pearson D.A., Swenson K., et al. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant 5 (1999) 133-143
4. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89 (1997) 4531-4536
5. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
6. Storb R., Yu C., Sandmaier B.M., et al. Mixed hematopoietic chimerism after marrow allografts. Transplantation in the ambulatory care setting. Ann N Y Acad Sci 872 (1999) 372-375
7. Spitzer T.R., McAfee S., Sackstein R., et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 6 (2000) 309-320
8. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97 (2001) 3390-3400
9. Jochum C., Beste M., Zellmer E., Graves S.S., and Storb R. CD154 blockade and donor-specific transfusions in DLA-identical marrow transplantation in dogs conditioned with 1-Gy total body irradiation. Biol Blood Marrow Transplant 13 (2007) 164-171
10. Zaucha J.M., Zellmer E., Georges G., et al. G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required. Biol Blood Marrow Transplant 7 (2001) 613-619
11. Zaucha J.M., Yu C., Zellmer E., et al. Effects of extending the duration of postgrafting immunosuppression and substituting granulocyte-colony-stimulating factor-mobilized peripheral blood mononuclear cells for marrow in allogeneic engraftment in a nonmyeloablative canine transplantation model. Biol Blood Marrow Transplant 7 (2001) 513-516
12. Panse J.P., Storb R., Storer B., Santos E.B., Wentzel C., and Sandmaier B.M. Prolonged allogeneic marrow engraftment following nonmyeloablative conditioning using 100 cGy total body irradiation and pentostatin before and pharmacological immunosuppression after transplantation. Transplantation 80 (2005) 1518-1521
13. Hilgendorf I., Weirich V., Zeng L., et al. Canine haematopoietic chimerism analyses by semiquantitative fluorescence detection of variable number of tandem repeat polymorphism. Vet Res Commun 29 (2005) 103-110
14. Lupu M., McCune J.S., Kuhr C.S., Gooley T., and Storb R. Pharmacokinetics of oral mycophenolate mofetil in dog: bioavailability studies and the impact of antibiotic therapy. Biol Blood Marrow Transplant 12 (2006) 1352-1354
15. Storb R., Raff R.F., Appelbaum F.R., et al. Fractionated versus single-dose total body irradiation at low and high dose rates to condition canine littermates for DLA-identical marrow grafts. Blood 83 (1994) 3384-3389
16. Childs R., Clave E., Contentin N., et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 94 (1999) 3234-3241
17. Baron F., Baker J.E., Storb R., et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 104 (2004) 2254-2262
18. Borrello I., Sotomayor E.M., Rattis F.M., Cooke S.K., Gu L., and Levitsky H.I. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 95 (2000) 3011-3019
19. Chen X., Zeng Y., Li G., Larmonier N., Graner M.W., and Katsanis E. Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity. Biol Blood Marrow Transplant 12 (2006) 275-283
20. Teshima T., Mach N., Hill G.R., et al. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res 61 (2001) 162-171
21. Ma J., Urba W.J., Si L., Wang Y., Fox B.A., and Hu H.M. Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur J Immunol 33 (2003) 2123-2132
22. Szabo G., Gavala C., MandrekarTacrolimus P., and cyclosporine A. inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells. J Invest Med 49 (2001) 442-449
23. Tajima K., Amakawa R., Ito T., Miyaji M., Takebayashi M., and Fukuhara S. Immunomodulatory effects of cyclosporin A on human peripheral blood dendritic cell subsets. Immunology 108 (2003) 321-328
24. Chklovskaia E., Nowbakht P., Nissen C., Gratwohl A., Bargetzi M., and Wodnar-Filipowicz A. Reconstitution of dendritic and natural killer-cell subsets after allogeneic stem cell transplantation: effects of endogenous flt3 ligand. Blood 103 (2004) 3860-3868
25. Petersdorf E.W. Risk assessment in haematopoietic stem cell transplantation: histocompatibility. Best Pract Res Clin Haematol 20 (2007) 155-170
26. Moyer J.S., Maine G., and Mule J.J. Early vaccination with tumor-lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects. Biol Blood Marrow Transplant 12 (2006) 1010-1019
27. Ito A., Fujioka M., Tanaka K., Kobayashi T., and Honda H. Screening of cytokines to enhance vaccine effects of heat shock protein 70-rich tumor cell lysate. J Biosci Bioeng 100 (2005) 36-42
28. Reddy V., Iturraspe J.A., Tzolas A.C., Meier-Kriesche H.U., Schold J., and Wingard J.R. Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease. Blood 103 (2004) 4330-4335
29. Fugier-Vivier I.J., Rezzoug F., Huang Y., et al. Plasmacytoid precursor dendritic cells facilitate allogeneic hematopoietic stem cell engraftment. J Exp Med 201 (2005) 373-383
30. Waller E.K., Rosenthal H., Jones T.W., et al. Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood 97 (2001) 2948-2956
31. Schott M. Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers. Endocr Relat Cancer 13 (2006) 779-795
32. Jonuleit H., Giesecke-Tuettenberg A., Tuting T., et al. 2001 A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 93 (2001) 243-251